BILL ANALYSIS

HR3413

BEARISH

Physician and Patient Safety Act

HR3413 (Physician and Patient Safety Act) carries an AI-assessed market impact score of 5/10 with a bearish outlook for investors. This legislation directly affects HCA Healthcare ($HCA) and $UHS. The primary sectors impacted are Healthcare. View the full bill text on Congress.gov.

5/10

Impact Score

bearish

Market Sentiment

Affected Stocks

Sectors Impacted

Key Takeaways for Investors

HR3413 is pure regulatory mandate with zero funding — no direct money trail for investors to follow.

Bill has not moved past committee referral in 11 months; companion bill also stalled in Senate.

If enacted, hospital operators ($HCA, $UHS) face minor administrative cost friction, but impact is immaterial to earnings.

No listed physician or healthcare services company has material revenue exposure to this procedural change.

How HR3413 Affects the Market

No actionable market implications. This bill does not alter reimbursement rates, coverage mandates, drug pricing, or any revenue driver for publicly traded healthcare companies. Hospital operators $HCA and $UHS would face negligible incremental compliance costs. Investors should monitor for unexpected movement (committee markup, inclusion in must-pass health legislation) but current baseline expectation is that HR3413 dies in committee.

Bill Details

Metric	Value
Bill Number	HR3413
Impact Score	5/10Certainty: Introduced/Referred (+1.0 companion bill) · Financial Magnitude: $70.0B — major funding · Strategic Weight: AI qualitative assessment: 2/10 · Market Penetration: 2 companies directly affected
Market Sentiment	bearish
Event Date	May 14, 2025
Affected Sectors	Healthcare
Affected Stocks	HCA Healthcare ($HCA), $UHS
Source	View on Congress.gov →

Summary

The Physician and Patient Safety Act (HR3413) is an early-stage bill that mandates due process procedures for physicians before hospitals can restrict staff privileges. The bill contains no direct funding, is referred to committee with only 6 cosponsors, and carries negligible near-term market impact for the healthcare sector.

Full AI Market Analysis

1) What happened: HR3413 was introduced in the House on May 14, 2025 by Rep. Ruiz (D-CA) and referred to the House Committee on Energy and Commerce. The bill has 6 cosponsors and an identical companion bill (S1767) in the Senate. As of today (April 30, 2026), the bill remains in committee with no further action — it is stalled in early stage. 2) The money trail: There is zero funding authorization or appropriation in this bill. It is a pure regulatory mandate — it instructs HHS to issue regulations requiring hospitals to provide fair hearings and appellate review before terminating or restricting physician staff privileges. No federal dollars flow. No tax credits, grants, or procurement programs are created. 3) Structural winners and losers: This is not a market-moving bill. Hospitals ($HCA, $UHS) face modest operational friction from additional administrative and legal procedures, but the cost is immaterial relative to their revenue bases (HCA's 2025 revenue ~$70B; UHS ~$16B). Physician staffing companies ($AMN, $CHG Healthcare private) could see minor benefits if the due-process protections make hospital employment less desirable, but this is speculative and not grounded in bill text. No clear winners. 4) Timeline: The bill requires HHS to issue final regulations within 18 months of enactment. However, the bill has not advanced out of committee in nearly a year. Without substantial committee leadership sponsorship or a broader legislative vehicle, passage in this Congress is unlikely.